Lead Product(s): PeptiCRAd
Therapeutic Area: Oncology
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Finnish Funding Agency for Innovation
Deal Size: $10.9 million Upfront Cash: $1.2 million
Deal Type: Funding February 06, 2020
The funding will enable Valo Therapeutics to further validate their platform to develop antigen-coated oncolytic viruses as therapeutic vaccines.